✦ LIBER ✦

Current literature highlights - February 2002

Book ID: 104438152
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 36 KB
Volume: 4
Category: Article
ISSN: 1464-3383
DOI: 10.1016/s1464-3383(04)80127-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Current literature highlights - January

Current literature highlights - January 2002

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 34 KB

## Nucleoside phosphoramidates Compounds containing the phosphoramidate functionality have a range of biological activities including acting as anticancer and cardioprotective agents. As phosphoric and carboxylic equivalents, phosphoramidates have been evaluated as analogues of nucleosides and olig

Current literature highlights - April 20

Current literature highlights - April 2002

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Current literature highlights - June 200

Current literature highlights - June 2002

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Current literature highlights - August 2

Current literature highlights - August 2002.

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 45 KB

## Cdk4 Inhibitors Cyclins and cyclin-dependent kinases (Cdks) play important roles in regulation of the cell cycle. In particular, D-type cyclins, which are activated by rearrangement or amplification in several tumours, associate Cdk4/6. Cyclin D-Cdk4/6 complexes phosphorylate the retinoblastoma

Current literature highlights - May 2001

📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 34 KB

## Bone resorption inhibitors The osteoclast vacuolar-ATPase plays an essential role in bone resorption, and inhibition of this acid pump has been shown to inhibit bone resorption both in vitro and in vivo. Inhibitors of bone resorption are potentially useful for the treatment of osteoporosis, i.e.

Current literature highlights - June 200

Current literature highlights - June 2001

📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Recently a number of groups have disclosed novel compounds derived from the peptidylprolyl isomerase (PPIase) inhibition domains of the immunosuppressive drugs FK506 and rapamycin. These non-immunosuppressive small molecules, with a molecular weigh of less than 500, were found to be potent neurotrop